Randall Rasmusson and Glenna Bett.

Cytocybernetics, the UB spinoff founded by Randall L. Rasmusson, PhD, left, and Glenna C. Bett, PhD, will expand into neuronal drug development thanks to a Small Business Innovation Research award.

UB Spinoff Cytocybernetics Receives Innovation Funding

Published November 20, 2018 This content is archived.

story based on news release by charlotte hsu

Cytocybernetics, a UB spinoff founded by two Jacobs School of Medicine and Biomedical Sciences faculty members, has received a $250,000 Small Business Innovation Research (SBIR) award from the National Institute of Mental Health (NIMH) to move into a new market: neuronal drug development.

“This award strengthens the notion of Western New York being an important region for early phase drug development. ”
Associate professor in the Department of Obstetrics and Gynecology and co-founder and CEO of Cytocybernetics

The startup developed and sells the Cybercyte, a device that integrates electronics with individual cells to test how new medicines affect the cell’s electrical activity.

Expansion Beyond Cardiac Applications

So far, Cytocybernetics’ focus has been on the heart: By linking the Cybercyte to heart muscle cells, scientists can test pharmaceuticals, from allergy medications to antidepressants, for potentially fatal side effects such as heart attacks.

The new SBIR funding will enable Cytocybernetics to expand beyond cardiac applications and develop the Cybercyte for use with brain cells, called neurons.

Will Study How Drugs Interact With Neurons

If successful, this advancement will allow researchers to use the Cybercyte to study how drugs being developed for neurological disorders — such as epilepsy and Parkinson’s disease — affect electrical activity within individual brain cells.

“This will enable neuroscientists to determine specific details of how drugs interact with neurons and affect their electrical behavior,” says Cytocybernetics CEO Glenna C. Bett, PhD, vice chair for research and associate professor in the Department of Obstetrics and Gynecology. “Whereas our work with heart cells is focused on drug safety screening, our work with neurons will target an earlier but equally important step in the drug development pipeline: studying how a drug works, and enabling scientists to more fully characterize early-stage candidate drugs with potential in neuroscience.”

Bett co-founded Cytocybernetics with Randall L. Rasmusson, PhD, professor in the Department of Physiology and Biophysics. Rasmusson is president of Cytocybernetics.

Key Region for Early Phase Drug Development

Bett says the new award from NIMH, part of the National Institutes of Health (NIH), will result in two new jobs at Cytocybernetics, adding to the firm’s current total of seven full-time employees, not including Bett and Rasmusson.

“This award strengthens the notion of Western New York being an important region for early phase drug development,” she says. “Dr. Mark Nowak, who joined Cytocybernetics as our lead scientist in 2015, will be overseeing our research on neuronal applications for the Cybercyte. He graduated from UB in 1992 with his PhD, went to Caltech, then worked in drug discovery in California before coming back to Buffalo to be part of the burgeoning health tech innovation culture here.”

Promotion of Medical Startups Paying Off

In recent years, UB and partners have worked to expand the region’s entrepreneurial ecosystem, devoting new resources to promoting the growth of startups. Cytocybernetics exemplifies how these investments — ranging from increased mentoring for faculty entrepreneurs to new sources of funding for research, development and commercialization — are paying off for Western New York.

Cytocybernetics is a past $500,000 winner in the 43North startup competition, and has also received funding through the SUNY Technology Accelerator Fund. The Business and Entrepreneur Partnerships team at UB helped Cytocybernetics secure critical, early-stage R&D funding through the UB Center for Advanced Technology in Big Data and Health Sciences (UB CAT) and coordinated acceptance to the START-UP NY program, allowing the company to operate for 10 years without paying various state taxes.

This early support from UB, SUNY and New York State helped the company develop the Cybercyte, leading to a $1.5 million Small Business Technology Transfer award from the National Heart, Lung, and Blood Institute — also part of the NIH — in 2017.